Hanmi Pharm's 'Gugu' Enters Japan as a Treatment for Benign Prostatic Hyperplasia

[Asia Economy Reporter Cho Hyun-ui] Hanmi Pharmaceutical's erectile dysfunction treatment 'Gugu' (active ingredient Tadalafil) has been launched in Japan as a treatment for benign prostatic hyperplasia.

Hanmi Pharmaceutical announced on the 23rd that its partner Sandoz received approval from Japan's Ministry of Health, Labour and Welfare in February for Gugu 2.5 mg and 5 mg as the first generic drugs for the treatment of benign prostatic hyperplasia.

Hanmi Pharmaceutical supplies the finished products, and Sandoz handles sales and marketing throughout Japan.

A Hanmi Pharmaceutical official stated, "Gugu has established itself as a leader in the domestic urology treatment market based on excellent product quality and trust," adding, "We will strive to achieve success in the Japanese market through cooperation with our partner Sandoz."

This content was produced with the assistance of AI translation services.